Up-regulation of inhibitors of DNA binding/differentiation gene during alendronate-induced osteoblast differentiation

Kang, Ae Ra; Oh, Young Rim; Kim, Heung Yeol; Park, Min Jung; Joo, Bo Sun; Choi, Woo June; Lee, Ji Young; Jung, Min Hyung; Ji, Yong; Choi, Jong Soon

doi:10.1007/s00404-011-2141-1

Cited by 16 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, it was identified that there was a significant difference in the level of runx2 between the control group and the sham group; this may be due to suppression of osteogenic growth following implantation of the prosthesis. Results of an in vitro study by Kang et al (45), examining the effects of ALN on osteoblasts, are inconsistent with the present results; this discrepancy may be caused by the difference in experimental materials. The study conducted by Kang et al was an in vitro experiment, whereas the present study observed effects in mice.…”

Section: Discussioncontrasting

confidence: 99%

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

et al. 2018

View full text Add to dashboard Cite

Aseptic loosening and menopause‑induced osteoporosis are caused by an imbalance between bone formation and osteolysis. With an aging population, the probability of simultaneous occurrence of such conditions in an elderly individual is increasing. Strontium ranelate (SR) is an anti‑osteoporosis drug that promotes bone formation and inhibits osteolysis. The present study compared the effects of SR with those of the traditional anti‑osteoporosis drug alendronate (ALN) using an ovariectomized mouse model of osteolysis. The degree of firmness of the prosthesis and the surrounding tissue was examined, a micro‑CT scan of the prosthesis and the surrounding tissue was performed, and the levels of inflammatory and osteogenic and osteoclast factors were examined. It was observed that treatment with SR and ALN improved the bond between the prosthesis and the surrounding bone tissue by reducing the degree of osteolysis, thus improving the quality of bone around the prosthesis. SR increased the secretion of osteocalcin, runt‑related transcription factor 2 and osteoprotegerin (OPG). It additionally decreased the expression of the receptor activator of nuclear factor‑κB ligand (RANKL) and consequently increased the protein ratio OPG/RANKL, whereas ALN exhibited the opposite effect. Furthermore, SR and ALN suppressed tumor necrosis factor‑α and interleukin‑1β production, with SR exerting a more marked effect. The present results demonstrate that SR and ALN may stimulate bone formation and inhibit bone resorption in the ovariectomized mouse model of wear particle‑mediated osteolysis, with SR demonstrating better effects compared with ALN.

show abstract

Section: Discussioncontrasting

confidence: 99%

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This is strongly supported by a previous study, 12 although some studies have shown that ALN treatment induces osteoblast differentiation and bone formation. 13,16 The difference could possibly be due to experimental systems used, including cell types, stages of cell differentiation (stem cells/osteoprogenitors vs. osteoblastic cells) and ALN concentrations.…”

Section: Resultsmentioning

confidence: 99%

Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis

2014

View full text Add to dashboard Cite

show abstract

“…Cell viability was determined using an MTT assay method previously reported . Cells were plated at a density of 1.0 × 10 4 per cm 2 in 96‐well plates.…”

Section: Methodsmentioning

confidence: 99%

“…Cell viability was determined using an MTT assay method previously reported. 21 Cells were plated at a density of 1.0 × 10 4 per cm 2 in 96-well plates. After reaching confluence, ZOL and ETI were added to the culture medium, then medium was removed at various time points and replaced with 50 μL of a solution containing 12.5-μg MTT, then further incubation was performed at 37°C.…”

Section: Mtt Assaymentioning

confidence: 99%

Suppressive effects of N‐bisphosphonate in osteoblastic cells mitigated by non‐N‐bisphosphonate but not by sodium‐dependent phosphate cotransporter inhibitor

Baba

Miyazaki

Ohara‐Nemoto

et al. 2019

Cell Biochemistry & Function

View full text Add to dashboard Cite

There are two types of bisphosphonates (BPs), nitrogen‐containing (N‐BPs) and those free from nitrogen (non‐N‐BPs). Although N‐BPs show greater inhibition of bone resorption than non‐N‐BPs, their effects are likely accompanied with inflammation, which non‐N‐BPs mitigate. We examined the competitive effects of zoledronate (ZOL), an N‐BP, and etidronate (ETI), a non‐N‐BP, in osteoblasts. ZOL, but not ETI, markedly reduced alkaline phosphatase activity and cell viability in osteoblastic MC3T3‐E1 and Saos2 cells, while that inhibition was relieved by simultaneous administration of ETI, possibly because of competition with ZOL for cellular uptake. However, phosphonoformate, an inhibitor of the phosphonate transporters SLC20A and SLC34A, did not mitigate the reducing effects of ZOL, suggesting that those transporters are not involved in BP uptake in osteoblastic cells. Additionally, ZOL reduced fibroblastic NIH3T3 and C3H10T1/2 cell viability, which was relieved by administration of both ETI and phosphonoformate. Transporter gene expression levels were significantly lower in osteoblasts as compared with fibroblasts, which may account for the distinct effects of phosphonoformate with different cell types. Together, our results suggest existence of a common uptake route of N‐BPs and non‐N‐BPs into osteoblastic cells that is unrelated to the SLC20A and SLC34A families. Significance of the study N‐BP ZOL was shown to suppress differentiation and viability of osteoblasts. ZOL‐induced cell viability suppression was also observed in fibroblasts, which was markedly relieved by addition of the non‐N‐BP ETI. Additionally, mitigation of the effects of ZOL was achieved with phosphonoformate, a sodium‐phosphate cotransporter inhibitor, in fibroblastic cells but not osteoblasts. Expression levels of SLC20A and SLC34A family genes were significantly lower in osteoblasts as compared with fibroblasts. These observations suggest that incorporation of N‐BPs and non‐N‐BPs in osteoblasts is mediated via common transporters that appear to be distinct from SLC20A and 34A, which operate in fibroblasts.

show abstract

Up-regulation of inhibitors of DNA binding/differentiation gene during alendronate-induced osteoblast differentiation

Cited by 16 publications

References 22 publications

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice

Alendronate-induced atypical bone fracture: evidence that the drug inhibits osteogenesis

Suppressive effects of N‐bisphosphonate in osteoblastic cells mitigated by non‐N‐bisphosphonate but not by sodium‐dependent phosphate cotransporter inhibitor

Contact Info

Product

Resources

About